| scholarly article | Q13442814 |
| P2093 | author name string | D. A. Thorley-Lawson | |
| C. M. Edson | |||
| P2860 | cites work | Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis | Q24632165 |
| MORPHOLOGICAL AND BIOLOGICAL STUDIES ON A VIRUS IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA | Q24679658 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| A Film Detection Method for Tritium-Labelled Proteins and Nucleic Acids in Polyacrylamide Gels | Q29547782 | ||
| Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus | Q34731769 | ||
| Immunofluorescence in cells derived from Burkitt's lymphoma. | Q35177017 | ||
| Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes | Q36335723 | ||
| Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells | Q36385482 | ||
| Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction | Q36460788 | ||
| DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus | Q36526302 | ||
| Mechanisms of infection with Epstein-Barr virus. I. Viral DNA replication and formation of noninfectious virus particles in superinfected Raji cells | Q36543663 | ||
| Tumor initiators and promoters in the induction of Epstein—Barr virus | Q37315125 | ||
| Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus | Q37500327 | ||
| Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus | Q37501980 | ||
| Immunochemical Characterization of Epstein-Barr Virus-Associated Early and Late Antigens in n -Butyrate-Treated P3HR-1 Cells | Q37601607 | ||
| Correlation Between Epstein-Barr Virus Membrane Antigen and Three Large Cell Surface Glycoproteins | Q37601655 | ||
| Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups | Q38896500 | ||
| Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A | Q39513417 | ||
| Epstein-Barr virus-induced membrane antigens: Immunochemical characterization of triton X-100 solubilized viral membrane antigens from EBV-superinfected raji cells | Q39558367 | ||
| Preparation and properties of lymphocyte plasma membrane | Q39949965 | ||
| Ultraviolet inactivation of Epstein-Barr virus: Effect on synthesis of virus-associated antigens | Q39952465 | ||
| Suppression of glycoprotein formation of Semliki Forest, influenza, and avian sarcoma virus by tunicamycin | Q40016113 | ||
| Persisting oncogenic herpesvirus induced by the tumour promoter TPA | Q40136715 | ||
| A new tumour-derived transforming strain of Epstein–Barr virus | Q40141830 | ||
| Activation of latent Epstein–Barr virus by antibody to human IgM | Q40185728 | ||
| Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells | Q40209275 | ||
| Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate | Q40227712 | ||
| Enhancement of Epstein-Barr virus replication in producer cell lines by a combination of low temperature and corticosteroids | Q40248874 | ||
| Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas | Q40259681 | ||
| A virus-free immunogen effective against Epstein-Barr virus | Q40262058 | ||
| Polypeptides of the Epstein-Barr virus membrane antigen complex | Q40268952 | ||
| Radioimmune precipitation study comparing the epstein-barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed on cells in a B-95 virus-transformed producer culture activated with tumor-promoting agent (TPA) | Q43971890 | ||
| Differential reactivity of human serums with early antigens induced by Epstein-Barr virus | Q44738097 | ||
| An immunoferritin study of a Burkitt lymphoma cell line harboring EB virus particles | Q44828244 | ||
| Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling | Q44982281 | ||
| Epstein-Barr virus-induced proteins. II. Analysis of surface polypeptides from EBV-producing and -superinfected cells by immunoprecipitation | Q45805937 | ||
| Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space | Q45814475 | ||
| Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence | Q45818353 | ||
| Appearance of Epstein-Barr virus-associated antigens in infected Raji cells | Q45821399 | ||
| Tunicamycin — An inhibitor of yeast glycoprotein synthesis | Q69349761 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| microbiology | Q7193 | ||
| immunology | Q101929 | ||
| P304 | page(s) | 172-184 | |
| P577 | publication date | 1981-07-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences | |
| P478 | volume | 39 |
| Q52317335 | An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. |
| Q36911884 | An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200) |
| Q38596344 | EBV Persistence--Introducing the Virus |
| Q41919826 | Early events in the infection of human B lymphocytes by Epstein-Barr virus: The internalization process |
| Q40131366 | Epstein-Barr Virus Antigens–A Challenge to Modern Biochemistry |
| Q45799685 | Epstein-Barr Virus induced proteins V: Comparison of EBV-specific polypeptides from different virus strains |
| Q36922358 | Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells |
| Q36884762 | Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. |
| Q39494552 | Epstein-Barr virus infection and immunoregulation in man. |
| Q45799506 | Epstein-Barr virus strain-specific differences in transformed cell lines demonstrated in growth characteristics, induction of viral antigens and ADCC susceptibility |
| Q36904686 | Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. |
| Q36888549 | Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells |
| Q45798341 | Glycosylation pathways of two major Epstein-Barr virus membrane antigens |
| Q24632150 | Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor |
| Q36903213 | Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2) |
| Q36923500 | Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo |
| Q36865571 | Identification of the Epstein-Barr virus gp85 gene |
| Q40139597 | Immunobiochemical characterization with monoclonal antibodies of Epstein-Barr virus-associated early antigens in chemically induced cells |
| Q36865623 | Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame |
| Q37562299 | Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists |
| Q36877989 | Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220. |
| Q36349979 | Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen |
| Q35676027 | Interaction of human tumor viruses with host cell surface receptors and cell entry |
| Q40064225 | Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340 |
| Q36312811 | Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection |
| Q45737839 | Molecular profile of a human monoclonal antibody Fab fragment specific for Epstein-Barr virus gp350/220 antigen |
| Q36889566 | Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein |
| Q34254100 | Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes |
| Q36873321 | Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. |
| Q40128299 | Strain-specific transcription and translation of the BamHI Z area of Epstein-Barr Virus. |
| Q36906049 | Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus |
| Q36928262 | The B95-8 isolate of Epstein-Barr virus arose from an isolate with a standard genome |
| Q39216150 | The Epstein-Barr virus proteins |
| Q36937184 | Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells |
| Q36901884 | Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene |
Search more.